Research Article
PDF EndNote BibTex RIS Cite

The relationship between malignancy and Behçet's disease features

Year 2022, Volume 5, Issue 2, 633 - 639, 15.03.2022
https://doi.org/10.32322/jhsm.1063623

Abstract

Introduction: Behçet’s disease (BD) is an autoimmune, multisystemic vasculitis characterized by chronic inflammation. Autoimmune responses in BD could drive chronic inflammation which is a risk for malignant transformation. Some genetic, environmental, clinical features and immunosuppressive treatments in BD may increase the risk of malignancy. Common genetic factors and similar environmental factors play a role in the pathogenesis of some autoimmune diseases and malignancies. We hypothesized that the frequency of comorbidity and clinical features of BD may differ in BD patients with a family history of malignancy. So, we aimed to compare the demographic and clinical characteristics features of the BD patients with and without a family history of malignancy. Material and Method: The BD patients who admitted the rheumatology outpatient clinic consecutively were included in the study. The demographic and clinical characteristics, comorbidities including malignancy in BD patients and malignancies in their family were questioned. The acute phase reactant elevation of at least two follow-ups was accepted as chronic inflammation. Results: A total of 98 patients (57% male) were included. Mean age was 43.5±12.3 years. The frequency of comorbidity was 60% and malignant/premalignant lesions were seen in 5% of the patients. All lesions were solid organ related and all of them were in women. History of BD and malignancy in patients' families was found 28% and 38%, respectively. The patients with and without malignancy in their family were compared. Female gender and the frequency of erythema nodosum were higher in the patients with malignancy in their family. The other demographic and clinical characteristics, chronic persistent inflammation and medical treatments were statistically. not different Conclusion: Frequency of malignancy in BD patients’ family was evaluated and to the best of our knowledge, there was no literature data on this subject interestingly. The family history of malignancy in BD patients could be associated with clinical characteristics. Further prospective studies were needed to show the clinical effect of malignancy history in families.

References

  • Cakir N, Dervis E, Benian O, et al. Prevalence of Behçet's disease in rural western Turkey: a preliminary report. Clin Exp Rheumatol 2004; 22: 53-5.
  • Fietta P. Behçet's disease: familial clustering and immunogenetics. Clin Exp Rheumatol 2005; 23: 96-105.
  • Yazici Y, Hatemi G, Bodaghi B, et al. Behçet syndrome. Nat Rev Dis Primers 2021; 7: 67.
  • Wang LH, Wang WM, Hsu SM, Lin SH, Shieh CC. Risk of overall and site-specific cancers in Behcet disease: a nation wide population-based study in Taiwan. J Rheumatol 2015; 42: 879-84
  • Na SJ, Kang MJ, Yu DS, et al. Cancer risk in patients with Behçet disease: A nationwide population-based dynamic cohort study from Korea. J Am Acad Dermatol 2018; 78: 464-70
  • Lin Y, Li G, Zheng W, Tian X, Zhang F. Behcet's disease associated with malignancy: a report of 41 Chinese cases. Int J Rheum Dis 2014; 17: 459-65
  • Cengiz M, Altundag MK, Zorlu AF, Güllü IH, Ozyar E, Atahan IL. Malignancy in Behçet's disease: a report of 13 cases and a review of the literature. Clin Rheumatol 2001; 20: 239-44.
  • Tada Y, Koarada S, Haruta Y, Mitamura M, Ohta A, Nagasawa K. The association of Behçet's disease with myelodysplastic syndrome in Japan: a review of the literature. Clin Exp Rheumatol 2007; 25: 507-8
  • Kaklamani VG, Tzonou A, Kaklamanis PG. Behçet's disease associated with malignancies. Report of two cases and review of the literature. Clin Exp Rheumatol 2005; 23: 35-41.
  • Gurcan M, Esatoglu SN, Hamuryudan V, et al. Long term follow-up of Behçet's syndrome patients treated with cyclophosphamide. Rheumatology (Oxford) 2020; 59: 2264-71.
  • Martin DN, Mikhail IS, Landgren O. Autoimmunity and hematologic malignancies: associations and mechanisms. Leuk Lymphoma 2009; 50: 541-50
  • Guven DC, Bolek EC, Altintop SE, et al. Cancer incidence in Behçet's disease. Ir J Med Sci 2020 ; 189: 1209-14.
  • Huang MX, Wang CY, Guo JY, et al. Pharmacotherapy for Behçet's Disease and the Risk of Malignancy. Front Pharmacol 2021; 12: 661150.
  • . Uçar F, Sönmez M, Ermantaş N, et al. The associations of HLA-A, -B, DRB1 alleles and haplotypes in Turkish lymphoma patients. Gene 2016; 586 : 263-7.
  • Xiao X, Liu L, Li WJ, Liu J, Chen DJ. HLA-A, HLA-B, HLA-DRB1 polymorphisms and risk of cervical squamous epithelial cell carcinoma: a population study in China. AsianPac J CancerPrev 2013; 14: 4427-33.
  • Shuxian J, Xiaoyun C, Zhihui F, et al. Association of HLA-B*51: 01 with papillary thyroid carcinoma in the Chinese Han population of the Shandong coastal areas. Thyroid 2014; 24: 867-71.
  • Sieverding M, Arbogast AL, Zintel S, von Wagner C. Gender differences in self-reported family history of cancer: A review and secondary data analysis. Cancer Med 2020; 9: 7772-80.
  • Krakow M, Rising CJ, Trivedi N, Yoon DC, Vanderpool RC. Prevalence and correlates of family cancer history knowledge and communication among US adults. Prev Chronic Dis 2020; 17: 146.
  • Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2018; 68: 297-316.
  • Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. Lancet 1990; 335: 1078-80.
  • Baecklund E, Smedby KE, Sutton LA, Askling J, Rosenquist R. Lymphoma development in patients with autoimmune and inflammatory disorders—whatare the driving forces? Semin Cancer Biol 2014; 24: 61-70.
  • Naramala S, Konala VM, Adapa S, et al. Trends in hospitalization and inpatient outcomes of behçet's disease: a nationwide inpatient sample study. Cureus 2020; 12: 7470.
  • Wang X, Peng Y, Gao J, Han S, Li Y. Risk of malignancy in Behcet disease: a meta-analysis with systematic review. Medicine (Baltimore) 2019; 98: 17735.
  • Na SY. Morbidity of solid cancer in Behcet’s disease: analysis of 11 cases in a series of 506 patients. Yonsei Med J 2013; 54: 895–901.
  • Kural-Seyahi E, Fresko I, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003; 82: 60-76.
  • Hidaka A, Sawada N, Svensson T, et al; JPHC Study Group. Family history of cancer and subsequent risk of cancer: A large-scale population-based prospective study in Japan. Int J Cancer 2020; 147: 331-7.

Year 2022, Volume 5, Issue 2, 633 - 639, 15.03.2022
https://doi.org/10.32322/jhsm.1063623

Abstract

References

  • Cakir N, Dervis E, Benian O, et al. Prevalence of Behçet's disease in rural western Turkey: a preliminary report. Clin Exp Rheumatol 2004; 22: 53-5.
  • Fietta P. Behçet's disease: familial clustering and immunogenetics. Clin Exp Rheumatol 2005; 23: 96-105.
  • Yazici Y, Hatemi G, Bodaghi B, et al. Behçet syndrome. Nat Rev Dis Primers 2021; 7: 67.
  • Wang LH, Wang WM, Hsu SM, Lin SH, Shieh CC. Risk of overall and site-specific cancers in Behcet disease: a nation wide population-based study in Taiwan. J Rheumatol 2015; 42: 879-84
  • Na SJ, Kang MJ, Yu DS, et al. Cancer risk in patients with Behçet disease: A nationwide population-based dynamic cohort study from Korea. J Am Acad Dermatol 2018; 78: 464-70
  • Lin Y, Li G, Zheng W, Tian X, Zhang F. Behcet's disease associated with malignancy: a report of 41 Chinese cases. Int J Rheum Dis 2014; 17: 459-65
  • Cengiz M, Altundag MK, Zorlu AF, Güllü IH, Ozyar E, Atahan IL. Malignancy in Behçet's disease: a report of 13 cases and a review of the literature. Clin Rheumatol 2001; 20: 239-44.
  • Tada Y, Koarada S, Haruta Y, Mitamura M, Ohta A, Nagasawa K. The association of Behçet's disease with myelodysplastic syndrome in Japan: a review of the literature. Clin Exp Rheumatol 2007; 25: 507-8
  • Kaklamani VG, Tzonou A, Kaklamanis PG. Behçet's disease associated with malignancies. Report of two cases and review of the literature. Clin Exp Rheumatol 2005; 23: 35-41.
  • Gurcan M, Esatoglu SN, Hamuryudan V, et al. Long term follow-up of Behçet's syndrome patients treated with cyclophosphamide. Rheumatology (Oxford) 2020; 59: 2264-71.
  • Martin DN, Mikhail IS, Landgren O. Autoimmunity and hematologic malignancies: associations and mechanisms. Leuk Lymphoma 2009; 50: 541-50
  • Guven DC, Bolek EC, Altintop SE, et al. Cancer incidence in Behçet's disease. Ir J Med Sci 2020 ; 189: 1209-14.
  • Huang MX, Wang CY, Guo JY, et al. Pharmacotherapy for Behçet's Disease and the Risk of Malignancy. Front Pharmacol 2021; 12: 661150.
  • . Uçar F, Sönmez M, Ermantaş N, et al. The associations of HLA-A, -B, DRB1 alleles and haplotypes in Turkish lymphoma patients. Gene 2016; 586 : 263-7.
  • Xiao X, Liu L, Li WJ, Liu J, Chen DJ. HLA-A, HLA-B, HLA-DRB1 polymorphisms and risk of cervical squamous epithelial cell carcinoma: a population study in China. AsianPac J CancerPrev 2013; 14: 4427-33.
  • Shuxian J, Xiaoyun C, Zhihui F, et al. Association of HLA-B*51: 01 with papillary thyroid carcinoma in the Chinese Han population of the Shandong coastal areas. Thyroid 2014; 24: 867-71.
  • Sieverding M, Arbogast AL, Zintel S, von Wagner C. Gender differences in self-reported family history of cancer: A review and secondary data analysis. Cancer Med 2020; 9: 7772-80.
  • Krakow M, Rising CJ, Trivedi N, Yoon DC, Vanderpool RC. Prevalence and correlates of family cancer history knowledge and communication among US adults. Prev Chronic Dis 2020; 17: 146.
  • Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2018; 68: 297-316.
  • Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. Lancet 1990; 335: 1078-80.
  • Baecklund E, Smedby KE, Sutton LA, Askling J, Rosenquist R. Lymphoma development in patients with autoimmune and inflammatory disorders—whatare the driving forces? Semin Cancer Biol 2014; 24: 61-70.
  • Naramala S, Konala VM, Adapa S, et al. Trends in hospitalization and inpatient outcomes of behçet's disease: a nationwide inpatient sample study. Cureus 2020; 12: 7470.
  • Wang X, Peng Y, Gao J, Han S, Li Y. Risk of malignancy in Behcet disease: a meta-analysis with systematic review. Medicine (Baltimore) 2019; 98: 17735.
  • Na SY. Morbidity of solid cancer in Behcet’s disease: analysis of 11 cases in a series of 506 patients. Yonsei Med J 2013; 54: 895–901.
  • Kural-Seyahi E, Fresko I, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003; 82: 60-76.
  • Hidaka A, Sawada N, Svensson T, et al; JPHC Study Group. Family history of cancer and subsequent risk of cancer: A large-scale population-based prospective study in Japan. Int J Cancer 2020; 147: 331-7.

Details

Primary Language English
Subjects Health Care Sciences and Services
Journal Section Original Article
Authors

İsmail DOĞAN> (Primary Author)
ANKARA YILDIRIM BEYAZIT UNIVERSITY, SCHOOL OF MEDICINE
0000-0002-7603-9484
Türkiye


Berkan ARMAĞAN>
Ankara Şehir Hastanesi
0000-0003-4409-059X
Türkiye


Kevser GÖK>
Ankara Şehir Hastanesi
0000-0001-8639-751X
Türkiye


Esra KAYACAN ERDOĞAN>
Ankara Şehir Hastanesi
0000-0002-3570-875X
Türkiye


Şükran ERTEN>
ANKARA YILDIRIM BEYAZIT ÜNİVERSİTESİ, TIP FAKÜLTESİ
0000-0003-0717-8365
Türkiye

Supporting Institution yok
Project Number yok
Publication Date March 15, 2022
Published in Issue Year 2022, Volume 5, Issue 2

Cite

Bibtex @research article { jhsm1063623, journal = {Journal of Health Sciences and Medicine}, eissn = {2636-8579}, address = {Kırıkkale Üniversitesi Tıp Fakültesi / İç Hastalıkları Anabilim Dalı}, publisher = {MediHealth Academy Yayıncılık}, year = {2022}, volume = {5}, number = {2}, pages = {633 - 639}, doi = {10.32322/jhsm.1063623}, title = {The relationship between malignancy and Behçet's disease features}, key = {cite}, author = {Doğan, İsmail and Armağan, Berkan and Gök, Kevser and Kayacan Erdoğan, Esra and Erten, Şükran} }
APA Doğan, İ. , Armağan, B. , Gök, K. , Kayacan Erdoğan, E. & Erten, Ş. (2022). The relationship between malignancy and Behçet's disease features . Journal of Health Sciences and Medicine , 5 (2) , 633-639 . DOI: 10.32322/jhsm.1063623
MLA Doğan, İ. , Armağan, B. , Gök, K. , Kayacan Erdoğan, E. , Erten, Ş. "The relationship between malignancy and Behçet's disease features" . Journal of Health Sciences and Medicine 5 (2022 ): 633-639 <https://dergipark.org.tr/en/pub/jhsm/issue/68828/1063623>
Chicago Doğan, İ. , Armağan, B. , Gök, K. , Kayacan Erdoğan, E. , Erten, Ş. "The relationship between malignancy and Behçet's disease features". Journal of Health Sciences and Medicine 5 (2022 ): 633-639
RIS TY - JOUR T1 - The relationship between malignancy and Behçet's disease features AU - İsmailDoğan, BerkanArmağan, KevserGök, EsraKayacan Erdoğan, ŞükranErten Y1 - 2022 PY - 2022 N1 - doi: 10.32322/jhsm.1063623 DO - 10.32322/jhsm.1063623 T2 - Journal of Health Sciences and Medicine JF - Journal JO - JOR SP - 633 EP - 639 VL - 5 IS - 2 SN - -2636-8579 M3 - doi: 10.32322/jhsm.1063623 UR - https://doi.org/10.32322/jhsm.1063623 Y2 - 2022 ER -
EndNote %0 Journal of Health Sciences and Medicine The relationship between malignancy and Behçet's disease features %A İsmail Doğan , Berkan Armağan , Kevser Gök , Esra Kayacan Erdoğan , Şükran Erten %T The relationship between malignancy and Behçet's disease features %D 2022 %J Journal of Health Sciences and Medicine %P -2636-8579 %V 5 %N 2 %R doi: 10.32322/jhsm.1063623 %U 10.32322/jhsm.1063623
ISNAD Doğan, İsmail , Armağan, Berkan , Gök, Kevser , Kayacan Erdoğan, Esra , Erten, Şükran . "The relationship between malignancy and Behçet's disease features". Journal of Health Sciences and Medicine 5 / 2 (March 2022): 633-639 . https://doi.org/10.32322/jhsm.1063623
AMA Doğan İ. , Armağan B. , Gök K. , Kayacan Erdoğan E. , Erten Ş. The relationship between malignancy and Behçet's disease features. J Health Sci Med / JHSM. 2022; 5(2): 633-639.
Vancouver Doğan İ. , Armağan B. , Gök K. , Kayacan Erdoğan E. , Erten Ş. The relationship between malignancy and Behçet's disease features. Journal of Health Sciences and Medicine. 2022; 5(2): 633-639.
IEEE İ. Doğan , B. Armağan , K. Gök , E. Kayacan Erdoğan and Ş. Erten , "The relationship between malignancy and Behçet's disease features", Journal of Health Sciences and Medicine, vol. 5, no. 2, pp. 633-639, Mar. 2022, doi:10.32322/jhsm.1063623

Interuniversity Board (UAK) Equivalency: Ulakbim TR Dizin and 1b [Original research article published in journals scanned by international field indexes (included in indices other than the ones mentioned in 1a) - 10 POINTS]. The Directories (indexes) and Platforms we are included in are at the bottom of the page.

Note: Our journal is not WOS indexed and therefore is not classified as Q.

You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show







The indexes of the journal are;

       images?q=tbn:ANd9GcRB9r6zRLDl0Pz7om2DQkiTQXqDtuq64Eb1Qg&usqp=CAU

500px-WorldCat_logo.svg.png

atifdizini.png

logo_world_of_journals_no_margin.png

images?q=tbn%3AANd9GcTNpvUjQ4Ffc6uQBqMQrqYMR53c7bRqD9rohCINkko0Y1a_hPSn&usqp=CAU

doaj.png  

images?q=tbn:ANd9GcSpOQFsFv3RdX0lIQJC3SwkFIA-CceHin_ujli_JrqBy3A32A_Tx_oMoIZn96EcrpLwTQg&usqp=CAU

ici2.png

asos-index.png

drji.png





The platforms of the journal are;

COPE-logo-300x199.jpgimages?q=tbn:ANd9GcQR6_qdgvxMP9owgnYzJ1M6CS_XzR_d7orTjA&usqp=CAU

icmje_1_orig.png

cc.logo.large.png

ncbi.pngimages?q=tbn:ANd9GcRBcJw8ia8S9TI4Fun5vj3HPzEcEKIvF_jtnw&usqp=CAU

ORCID_logo.png

1*mvsP194Golg0Dmo2rjJ-oQ.jpeg


Our Journal using the DergiPark system indexed are;

Ulakbim TR Dizin,  Index Copernicus, ICI World of JournalsDirectory of Research Journals Indexing (DRJI), General Impact FactorASOS Index, OpenAIRE, MIAR,  EuroPub, WorldCat (OCLC)DOAJ,  Türkiye Citation Index, Türk Medline Index, InfoBase Index


Our Journal using the DergiPark system platforms are;

Google, Google Scholar, CrossRef (DOI), ResearchBib, ICJME, COPE, NCBI, ORCID, Creative Commons, Open Access, and etc.


Journal articles are evaluated as "Double-Blind Peer Review". 

Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user.  https//dergipark.org.tr/tr/pub/jhsm/page/9535

Journal charge policy   https://dergipark.org.tr/tr/pub/jhsm/page/10912


Editor List for 2022

Assoc. Prof. Alpaslan TANOĞLU (MD)  

Prof. Aydın ÇİFCİ (MD)

Prof. İbrahim Celalaettin HAZNEDAROĞLU (MD)

Prof. Murat KEKİLLİ (MD)

Prof. Yavuz BEYAZIT (MD) 

Prof. Ekrem ÜNAL (MD)

Prof. Ahmet EKEN (MD)

Assoc. Prof. Ercan YUVANÇ (MD)

Assoc. Prof. Bekir UÇAN (MD) 

Assoc. Prof. Mehmet Sinan DAL (MD)


Our journal has been indexed in DOAJ as of May 18, 2020.

Our journal has been indexed in TR-Dizin as of March 12, 2021.


17873

Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.